Madrigal Pharmaceuticals Inc (STU:YDO1) Stock News, Headlines & Updates
Madrigal Pharmaceuticals Inc Stock News from GuruFocus
- 1
- 2
Jul 22, 2025
Madrigal Pharmaceuticals (MDGL) Secures $500 Million Credit Facility
GuruFocus News • 7:59am
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH | MDGL Stock News
GuruFocus News • 7:22am
Madrigal Pharmaceuticals Secures $500 Million Credit Facility to Boost MASH Pipeline | MDGL stock news
GuruFocus News • 7:07am
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
Marketwired • 7:00am
Jul 16, 2025
Madrigal Pharmaceuticals Inc (MDGL) Announces Equity Awards for New Employees | MDGL stock news
GuruFocus News • 4:00pm
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Marketwired • 4:00pm
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | MDGL Stock News
GuruFocus News • 3:21pm
Madrigal Pharmaceuticals (MDGL) Surges Over 12% in Market Gains | MDGL Stock News
GuruFocus News • 11:15am
Madrigal Pharmaceuticals (MDGL) Soars on Rezdiffra Patent Approval
GuruFocus News • 8:55am
Madrigal Pharmaceuticals (MDGL) Gains on Patent Progress for Rezdiffra | MDGL Stock News
GuruFocus News • 8:45am
Madrigal Pharmaceuticals (MDGL) Secures Patent for Rezdiffra Use | MDGL Stock News
GuruFocus News • 7:18am
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffraâ„¢ (Resmetirom)
Marketwired • 7:00am
Jun 26, 2025
Madrigal Pharmaceuticals (MDGL) Sees Stock Surge After Competitor's Trial Outcome
GuruFocus News • 2:56pm
Jun 20, 2025
Madrigal Pharmaceuticals (MDGL) Gains EU Regulatory Support for Rezdiffra
GuruFocus News • 8:58am
Madrigal Pharmaceuticals Inc (MDGL) Receives Positive CHMP Opinion for Resmetirom in Treating MASH | MDGL stock news
GuruFocus News • 6:02am
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffraâ„¢) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
Marketwired • 6:00am
Madrigal Pharmaceuticals (MDGL) Gains EU Backing for Liver Treatment | MDGL Stock News
GuruFocus News • 5:47am
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffraâ„¢) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis | MDGL Stock News
GuruFocus News • 5:45am
Jun 17, 2025
Madrigal Pharmaceuticals Inc (MDGL) Announces Equity Awards for New Employees | MDGL stock news
GuruFocus News • 4:09pm
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Marketwired • 4:00pm
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | MDGL Stock News
GuruFocus News • 3:18pm
Jun 02, 2025
Madrigal Pharmaceuticals Inc (MDGL) to Present at Goldman Sachs Health Care Conference | MDGL stock news
GuruFocus News • 8:03am
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
Marketwired • 7:00am
May 15, 2025
John Paulson's Strategic Move: Honeywell International Inc. Takes Center Stage
GuruFocus News • 5:21pm
May 11, 2025
MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra | MDGL Stock News
GuruFocus News • 12:30pm
May 10, 2025
Madrigal Pharmaceuticals Inc (MDGL) Announces Promising Two-Year Results from Phase 3 MAESTRO-NAFLD-1 Trial | MDGL stock news
GuruFocus News • 8:01am
Madrigal Announces New Clinical Data Demonstrating Rezdiffraâ„¢ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
Marketwired • 7:00am
Madrigal Announces New Clinical Data Demonstrating Rezdiffraâ„¢ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis |
GuruFocus News • 6:30am
May 03, 2025
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT Insight
GuruFocus News • 11:04pm
May 02, 2025
Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raises Price Target | MDGL Stock News
GuruFocus News • 6:01pm
Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost from B. Riley Securities | MDGL Stock News
GuruFocus News • 11:39am
Madrigal Pharmaceuticals (MDGL) Target Price Raised by Canaccord Genuity | MDGL Stock News
GuruFocus News • 11:34am
UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | MDGL Stock News
GuruFocus News • 8:49am
Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Strong Sales | MDGL Stock News
GuruFocus News • 8:00am
Madrigal Pharmaceuticals (MDGL) Receives Increased Price Target from Analyst | MDGL Stock News
GuruFocus News • 6:34am
Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Expansion
GuruFocus News • 1:02am
Q1 2025 Madrigal Pharmaceuticals Inc Earnings Call Transcript
GuruFocus News • 11:16pm
May 01, 2025
Madrigal Pharmaceuticals Inc Q1 2025 Earnings: Revenue Surpasses Estimates at $137.3 Million, Operating Loss Reported
GuruFocus News • 6:33am
Madrigal Pharmaceuticals (MDGL) Reports Strong Q1 Revenue Exceeding Expectations | MDGL Stock News
GuruFocus News • 6:17am
- 1
- 2
Show
Entries
Headlines
Total 0- 1
No recent news